PEB - Pacific Edge profile
This is a basic profile of an NZX50 listed company. It is not investment advice. We recommend you contact a qualified adviser if you need more information.
|Short name:||Pacific Edge|
|Legal name:||Pacific Edge Limited|
|Industry sector:||Cancer Research|
|NZX50 rank:||41 of 50|
|Head office address:||Level 10, Otago House, Cnr Moray Place and Princes Street, Dunedin|
|Chief executive:||David Darling|
|Financial year ended:||March|
|Bankers:||BNZ, ANZ, Heartland Bank, (Dunedin)|
Financial statement history
A. Recent trading and performance summary:
B. Recent financial position summary:
C. Recent cash flows and positions:
|Cash and equiv.
at year end
Description of trading activities
Pacific Edge is a cancer diagnostics company. They develop and commercialize diagnostic and prognostic tools for early detection and management of Cancers.
David Darling has 30 years' experience in life sciences and biotech. He became CEO in 2014. He has held a number of positions in governance, executive and senior management joining Pacific Edge from Fletcher Challenge.
Chris Gallaher joined the board in 2016. He became chairman in August of 2016. He has held position in both CEO and CFO roles with a number of large international companies and was a partner in Arthur Young Chartered accountants. He was previously CFO of Fulton Hogan.